BENJAMIN J. ZESKIND - 03 Aug 2021 Form 4 Insider Report for Immuneering Corp (IMRX)

Role: President and CEO, Director, 10%+ Owner
Signature: By: /s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Issuer symbol: IMRX
Transactions as of: 03 Aug 2021
Net transactions value: +$31,470
Form type: 4
Filing time: 04 Aug 2021, 06:06:25 UTC
Previous filing: 29 Jul 2021
Next filing: 14 Sep 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IMRX	Class A Common Stock	Conversion of derivative security		+49,099	+1.9%		2,598,171	03 Aug 2021	Direct	F1
transaction	IMRX	Class A Common Stock	Purchase	$31,470	+2,098	+0.08%	$15.00	2,600,269	03 Aug 2021	Direct
holding	IMRX	Class A Common Stock						544,927	03 Aug 2021	See Foonote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMRX	Series A Preferred Stock	Conversion of derivative security		-40,928	-100%		0	03 Aug 2021	Class A Common Stock	40,928		Direct	F1
transaction	IMRX	Series B Preferred Stock	Conversion of derivative security		-8,171	-100%		0	03 Aug 2021	Class A Common Stock	8,171		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Immediately prior to the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's Class A common stock on a one-for-one basis.
F2	Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.